News from naurex inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 22, 2011, 07:30 ET Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it...


May 11, 2011, 07:00 ET Naurex Completes $18 Million Series A Financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the...


Dec 07, 2010, 07:30 ET New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, reported that data being...


Nov 17, 2010, 07:30 ET Preclinical Data at Neuroscience 2010 Show Naurex's Novel Antidepressant GLYX-13 Shares Key Efficacy Mechanisms with Ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at...


Aug 31, 2010, 07:30 ET Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical...


Jun 17, 2010, 11:25 ET Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13 at NCDEU 50th Anniversary Meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented...


Feb 10, 2010, 07:00 ET Naurex Inc. Reports Positive Top-Line Phase I Results for Its Novel Mechanism NMDA Receptor Modulator GLYX-13 in Treatment-Resistant Depression

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site...


Dec 16, 2009, 07:45 ET Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel...


Dec 16, 2009, 07:45 ET Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA...